Treosulfan: Difference between revisions
No edit summary |
m Protected "Treosulfan": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
| verifiedrevid = 447997363 | | verifiedrevid = 447997363 | ||
| IUPAC_name = (2''S'',3''S'')-2,3-Dihydroxybutane-1,4-diyl dimethanesulfonate | | IUPAC_name = (2''S'',3''S'')-2,3-Dihydroxybutane-1,4-diyl dimethanesulfonate | ||
| image = Treosulfan. | | image = Treosulfan.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 36: | Line 36: | ||
| molecular_weight = 278.30056 g·mol<sup>−1</sup> | | molecular_weight = 278.30056 g·mol<sup>−1</sup> | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Treosulfan''' is a [[Chemical substance|substance]] that is being studied in the treatment of [[cancer]].<ref name="pmid16971664">{{cite journal |author=Schmittel A, Schmidt-Hieber M, Martus P, ''et al.'' |title=A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma |journal=Ann. Oncol. |volume=17 |issue=12 |pages=1826–9 |date=December 2006 |pmid=16971664 |doi=10.1093/annonc/mdl309 |url=http://annonc.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16971664}}</ref> It belongs to the family of drugs called [[alkylating agents]]. It has been used mainly as a substitute of [[busulfan]] in frail patients, as the side effects and [[toxicity]] are supposedly less severe. | '''Treosulfan''' is a [[Chemical substance|substance]] that is being studied in the treatment of [[cancer]].<ref name="pmid16971664">{{cite journal |author=Schmittel A, Schmidt-Hieber M, Martus P, ''et al.'' |title=A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma |journal=Ann. Oncol. |volume=17 |issue=12 |pages=1826–9 |date=December 2006 |pmid=16971664 |doi=10.1093/annonc/mdl309 |url=http://annonc.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16971664}}</ref> It belongs to the family of drugs called [[alkylating agents]]. It has been used mainly as a substitute of [[busulfan]] in frail patients, as the side effects and [[toxicity]] are supposedly less severe. | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==External links== | ==External links== | ||
| Line 50: | Line 54: | ||
[[Category:IARC Group 1 carcinogens]] | [[Category:IARC Group 1 carcinogens]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 17:19, 20 August 2015
 | |
| Clinical data | |
|---|---|
| Synonyms | 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, IV |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6H14O8S2 |
| Molar mass | 278.30056 g·mol−1 |
  (what is this?) (verify) | |
|
WikiDoc Resources for Treosulfan |
|
Articles |
|---|
|
Most recent articles on Treosulfan |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Treosulfan at Clinical Trials.gov Clinical Trials on Treosulfan at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Treosulfan
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Treosulfan Discussion groups on Treosulfan Patient Handouts on Treosulfan Directions to Hospitals Treating Treosulfan Risk calculators and risk factors for Treosulfan
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Treosulfan |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References
- ↑ Schmittel A, Schmidt-Hieber M, Martus P; et al. (December 2006). "A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma". Ann. Oncol. 17 (12): 1826–9. doi:10.1093/annonc/mdl309. PMID 16971664.
External links
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Wikipedia articles incorporating text from the National Cancer Institute Dictionary of Cancer Terms
- IARC Group 1 carcinogens
- Drug